Cover Image
市場調查報告書

多囊性卵巢症候群:開發中產品分析

Polycystic Ovarian Syndrome - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 232830
出版日期 內容資訊 英文 50 Pages
訂單完成後即時交付
價格
Back to Top
多囊性卵巢症候群:開發中產品分析 Polycystic Ovarian Syndrome - Pipeline Review, H1 2017
出版日期: 2017年03月31日 內容資訊: 英文 50 Pages
簡介

多囊性卵巢症候群(PCOS)是育齡期女性會發生的荷爾蒙(內分泌)障礙。其症狀有月經異常,痤瘡,毛髮稀疏,體重增加,雄激素過剩等。危險因素有家族病史,第二型糖尿病,心臟病等,可用荷爾蒙療法加以治療。

本報告提供多囊性卵巢症候群治療藥的開發情形相關調查,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢等資訊。

簡介

  • 調查範圍

多囊性卵巢症候群概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

企業開發中的產品

大學/機關研究中的產品

治療藥的開發企業

  • Addex Therapeutics Ltd
  • Crinetics Pharmaceuticals, Inc.
  • EffRx Pharmaceuticals S.A.
  • Euroscreen S.A.
  • Merck KGaA
  • Millendo Therapeutics, Inc.
  • Vicore Pharma AB

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9114IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H1 2017, provides an overview of the Polycystic Ovarian Syndrome (Women's Health) pipeline landscape.

Polycystic ovary syndrome (PCOS) is a common hormonal disorder among women of reproductive age. Symptoms include menstrual abnormality, acne, thinning hair on the scalp, weight gain, excess androgen and polycystic ovaries. The main risk factor for polycystic ovary syndrome (PCOS) is a family history. Other factors include type 2 diabetes and heart disease. Treatment includes hormone therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Polycystic Ovarian Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Polycystic Ovarian Syndrome (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Polycystic Ovarian Syndrome (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Polycystic Ovarian Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Discovery and Unknown stages are 1, 3, 1, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Polycystic Ovarian Syndrome (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Polycystic Ovarian Syndrome (Women's Health).
  • The pipeline guide reviews pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Polycystic Ovarian Syndrome (Women's Health) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Polycystic Ovarian Syndrome (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Polycystic Ovarian Syndrome (Women's Health)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Polycystic Ovarian Syndrome (Women's Health).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Polycystic Ovarian Syndrome (Women's Health) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Polycystic Ovarian Syndrome - Overview
    • Polycystic Ovarian Syndrome - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Pipeline by Universities/Institutes
    • Products under Development by Companies
    • Products under Development by Universities/Institutes
  • Polycystic Ovarian Syndrome - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Polycystic Ovarian Syndrome - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Crinetics Pharmaceuticals Inc
    • EffRx Pharmaceuticals SA
    • Millendo Therapeutics Inc
    • Ogeda SA
    • Vicore Pharma AB
  • Polycystic Ovarian Syndrome - Drug Profiles
    • C-21 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Drug to Inhibit Interferon Gamma for Metabolic Disorders and Women's Health - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fezolinetant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • JDSCR-004 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • KDT-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • metformin hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • MLE-4901 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit KISS-1R for Polycystic Ovarian Syndrome - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Polycystic Ovarian Syndrome - Dormant Projects
  • Polycystic Ovarian Syndrome - Discontinued Products
  • Polycystic Ovarian Syndrome - Product Development Milestones
    • Featured News & Press Releases
      • Dec 20, 2016: Ogeda announces fezolinetant as INN and issuance of U.S. patent for ESN364
      • Nov 03, 2016: Millendo Therapeutics Announces Data Presentations at Androgen Excess and Polycystic Ovary Syndrome Society Annual Meeting
      • Nov 02, 2016: Millendo Therapeutics to present data on MLE-4901 program at Society for Endocrinology British Endocrine Societies Conference
      • Aug 16, 2016: Millendo Therapeutics Announces Initiation of Phase 2b Clinical Trial of MLE4901 in Patients with Polycystic Ovary Syndrome
      • Jul 27, 2016: Millendo Therapeutics Announces Publication of Positive Phase 2a Data for MLE4901 for the Treatment of Polycystic Ovary Syndrome
      • Jul 19, 2016: EUROSCREEN opens US-IND for ESN364 on three Phase II trials
      • Apr 21, 2015: Euroscreen starts in parallel two Phase 2 clinical trials with ESN364 in UF and PCOS patients
      • Dec 08, 2014: Euroscreen Announces Positive Completion of Phase I Trial of ESN364
      • Jun 20, 2014: Euroscreen ESN364 drug candidate presented at the ICE/ENDO Meeting
      • Jun 10, 2014: EffRx Receives U.S. Orphan Drug Designation for EX404 for Treatment of Pediatric Polycystic Ovary Syndrome
      • Dec 18, 2013: Euroscreen Initiates Phase I Clinical Trial For ESN364
      • Oct 01, 2013: EffRx Receives Prestigious EUR 5.9 Million FP7 Research Grant for the Development of EX404 for Polycystic Ovary Syndrome in Paediatric Populations
      • Feb 05, 2013: Euroscreen to present ESN364 drug candidate at the 11th International Symposium on GnRH
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Polycystic Ovarian Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Polycystic Ovarian Syndrome - Pipeline by Addex Therapeutics Ltd, H1 2017
  • Polycystic Ovarian Syndrome - Pipeline by Crinetics Pharmaceuticals Inc, H1 2017
  • Polycystic Ovarian Syndrome - Pipeline by EffRx Pharmaceuticals SA, H1 2017
  • Polycystic Ovarian Syndrome - Pipeline by Millendo Therapeutics Inc, H1 2017
  • Polycystic Ovarian Syndrome - Pipeline by Ogeda SA, H1 2017
  • Polycystic Ovarian Syndrome - Pipeline by Vicore Pharma AB, H1 2017
  • Polycystic Ovarian Syndrome - Dormant Projects, H1 2017
  • Polycystic Ovarian Syndrome - Discontinued Products, H1 2017

List of Figures

  • Number of Products under Development for Polycystic Ovarian Syndrome, H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top